Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Janus Henderson Group PLC increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 43.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,041,724 shares of the company's stock after buying an additional 313,019 shares during the quarter. Janus Henderson Group PLC owned 2.21% of Enliven Therapeutics worth $26,611,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Verition Fund Management LLC purchased a new stake in Enliven Therapeutics during the third quarter worth about $271,000. Walleye Capital LLC purchased a new stake in Enliven Therapeutics during the 3rd quarter worth about $2,539,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Enliven Therapeutics by 12.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after acquiring an additional 2,944 shares during the period. Ally Bridge Group NY LLC bought a new position in Enliven Therapeutics in the 3rd quarter valued at $5,998,000. Finally, FMR LLC boosted its stake in Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after buying an additional 601,611 shares during the period. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Price Performance

Shares of ELVN traded up $2.17 during midday trading on Friday, reaching $25.42. The stock had a trading volume of 188,373 shares, compared to its average volume of 201,494. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $30.03. The company's 50-day moving average is $26.79 and its 200 day moving average is $24.14.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 2,000 shares of the firm's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 7,522 shares of Enliven Therapeutics stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $206,930.22. Following the completion of the transaction, the insider now owns 1,069,887 shares in the company, valued at approximately $29,432,591.37. This represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 129,195 shares of company stock valued at $3,581,772 over the last quarter. 29.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ELVN. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, November 15th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.